138results about How to "Reduce the number of injections" patented technology

The invention discloses a novel fusion protein, a pharmaceutical composition formed by the novel fusion protein, a preparation method for the novel fusion protein and use of the novel fusion protein. According to novel fusion protein, the structural general formula is X-connecting peptide-Y-connecting peptide-IgG Fc fragment or Y-connecting peptide-X-connecting peptide-IgG Fc fragment, wherein X is VEGF-Trap and derivatives thereof, and Y is a PD-1 antibody fragment and derivatives thereof or a PD-1 antagonist fragment and derivatives thereof. The fusion protein plays roles in suppressing regenerated blood vessels and activating T cellular immunity and plays a role in coordinating and promoting two functions, so that the function of inhibiting tumor growth is more remarkable.

The invention discloses a film transistor and a manufacturing method thereof. The manufacturing method comprises the following steps: manufacturing a buffer layer on a substrate; manufacturing a polycrystalline silicon layer after ion doping on the buffer layer, wherein the concentrations of doped ions of the polycrystalline silicon layer after ion doping is distributed in a high-to-low gradient manner from the upper surface to the lower surface of the polycrystalline silicon layer; etching the polycrystalline silicon layer to form a concave silicon island, wherein the sunken part of the concave silicon island is a channel region, and a convex part is a source drain region; successively forming a gate-insulation layer, a gate layer, an interlayer insulation layer and a source drain electrode on the concave silicon island. The film transistor and the manufacturing method thereof, disclosed by the invention, have the advantages that an ion implantation technology is adopted, or the doping concentration is controlled in a PECVD (plasma enhanced chemical vapor deposition) technology, so that the purpose of the vertical gradient of the density of the doped ions is realized, and the number of times of implanting the ions is omitted or reduced; besides, the number of photomasks in a film transistor technology can be reduced, and the process complexity is reduced; in addition, the vertical concentration gradient can form an LDD (laser detector diode) structure, so that TFT (thin film transistor) leak currents are reduced.

The invention discloses a GLP-I analogue liraglutide sustained-release microspheres and a preparation method thereof. The GLP-I analogue liraglutide sustained-release microspheres comprise, by weight, 0.5 to 30% (w / w) of GLP-I analogue liraglutide, 70 to 99.5% of a polymer which has the molecular weight of 5000 to 300000 dalton, can be biodegraded and has biocompatibility, and 0 to 10% of pharmaceutically acceptable auxiliary materials. The GLP-I analogue liraglutide sustained-release microspheres have the average grain size of 5 to 40 micrometers and an encapsulation ratio more than 90%. The GLP-I analogue liraglutide sustained-release microspheres have a sustained-release period of several days or several months, obviously reduce use frequency, improve GLP-I analogue liraglutide bioavailability, reduce toxic and side effects and are conducive to clinical treatment.

The invention discloses a recombinant porcine follicle-stimulating hormone-Fc fusion protein (pFSH-Fc) and a preparation method thereof. The fusion protein is a dimerized fusion protein, wherein the amino acid sequence of the fusion protein sequentially comprises pFSH beta subunits, carboxy-terminal peptide (CTP), pFSH alpha subunits, peptide connectors and human IgG Fc variants from a terminal N to a terminal C. Compared with existing pFSH, the pFSH-Fc has a longer in-vivo half-life period and better efficacies. The invention further relates to application of the pFSH-Fc to preparation of medicaments in the animal breeding fields.

The invention is concerned with a kind of preparation method of inactivated vaccine to prevent new castle disease, infectious bronchitis and egg drop syndrome vaccine. The selected genus is Newcastle Disease virus La Sota individual plant, infectious bronchitis virus M41 individual plant, HN99 kidney type of aberrance individual plant and EDS76 Jing 911 individual plant. Dilute three kinds of virus and inoculate in the allantoic cavity of SPF chick embryo and affectable duck embryo. Collect liquid of embryo to alive and dead embryos as seed. Dilute and inoculate in allantoic cavity of affectable chick embryo or duck embryo to get liquid of virus embryo. Concentrate with equipment and add with formaldehyde solution to prepare bacterin through emulsion process. This invention can prevent Newcastle Disease, chick kidney type and breathing type infectious bronchitis, and egg drop syndrome vaccine. It can reduce the times of injection and the cost of epidemic prevention for easy using and practicality.

The invention pertains to a pharmaceutical preparation field, and in particular relates to a zinc protamine insulin ampoule injection and a preparation method thereof. The zinc protamine insulin ampoule injection comprises insulin, isotonizing agent, antiseptic agent, pH regulator, protamine sulfate and bi-distilled water for injection, wherein, the bi-distilled water for injection contains divalent zinc salt and the concentration of zinc ion is 0.01-0.04g per100000IU of insulin. The injection of the invention has the advantages that minim zinc ion is added into the insulin to form a stable polymer, which stabilizes the insulin and has a prolonged curative effect; the invention has simple, scientific and reasonable preparation and easy manipulation. The insulin can exist in two patterns: firstly, in liquor with quick effect; secondly, combining with protamine sulfate and in precipitation with action characters of both two insulin preparations, which reduces injection time and pain caused by rejection. Animal insulin is used for the injection, thus reducing the cost.

The invention relates to the technical field of veterinary administration, in particular to a veterinary ciprofloxacin lactate injection. The veterinary ciprofloxacin lactate injection consists of the following components in percentage by weight: 4-10 percent of ciprofloxacin lactate counted by ciprofloxacin, 10-15 percent of polyoxyethylene 40 hydrogenated castor oil, 0.5-1.0 percent of carbomer, 0.1 percent of sodium bisulfite, 0.01 percent of ethylene diamine tetraacetic acid, and the balance of water for injection. The injection is convenient to use; compared with the conventional injection, the veterinary ciprofloxacin lactate injection has the advantages: the injection times are reduced from twice a day to once a day, treatment cost is saved, stress caused by repeated injection for animals is reduced, and medicament tolerance of bacteria is avoided; the veterinary ciprofloxacin lactate injection has low toxicity and a reliable curative effect, acts for a long time, and can be used for effectively treating white scour of piglets and white diarrhea; and the swine muscle injection half-life period is 22.96 hours, which is equivalent to five times that of an ordinary injection (4.6 hours).

The invention discloses an energy storage device. The energy storage device comprises a shell, a battery core, an anode inner terminal, a cathode inner terminal, a cathode outer terminal and electrolyte, wherein the anode inner terminal and the cathode inner terminal are respectively welded on the end surfaces of an anode and a cathode of the battery core, and the periphery of the anode inner terminal is inserted in an annular groove on the bottom wall of the shell; a welding seam is formed in a way that the cathode inner terminal and the cathode outer terminal are welded together, an O-shaped sealing ring can cover the welding seam, and a roll rim at the opening part of the shell is pressed on the cathode outer terminal through an annular sealing washer; an upper annular side bulge and a lower annular side bulge, which face the inner part of the shell and have pressing functions, are respectively arranged in the positions, which correspond to the cathode inner terminal and the anode inner terminal, on the side wall of the shell. The invention also discloses an assembling method of the energy storage device. The energy storage device disclosed by the invention has the advantages that the stability is good, the resistance is low, and the reliability is good; the structure is simple, the machining and forming cost is low, and the assembling is easy.

The present invention discloses a variable doped junction terminal preparation method. An etching barrier layer is processed on the surface of a dielectric layer to form an echelonment medium morphology and then form the junction terminal of a grading structure through ion implantation. Through strictly controlling the etching speed ratio of two layers of medium, the variable doped junction terminal preparation method realizes step height accurate control and avoids the injection medium film thickness changing caused by etching ratio drifting. The injection dosage of each area of the junction terminal may be accurately controlled, and the number of times of ion injection in the device processing is reduced.

The invention relates to a pharmaceutical composition using liensinine to work in coordination with doxorubicin for chemotherapy and an application method of the pharmaceutical composition. The pharmaceutical composition comprises a liensinine injection solution and a chemotherapy drug doxorubicin injection solution. The application method comprises the following steps: (1) performing intravenous injection of liensinine once daily according to the dose that actual dosage in the liensinine injection solution to the body weight of a patient is equal to 4.88mg / kg; (2) performing intravenous injection of doxorubicin once according to the dose that the actual dosage in the doxorubicin injection solution to the body weight of the patient is equal to 0.16mg / kg on the day of injecting liensinine according to the step (1); (3) performing intravenous injection of the doxorubicin injection solution once again according to the dose in the step (2) on the sixth day; and (4) determining whether to circulate according to the method of the steps (1)-(3) or not, the number of circulation times and the intermediate drug withdrawal time from the eleventh day according to the bearing capacity and the treatment effect of a patient body. Compared with the prior art, in the aspect of inhibiting and killing various malignant tumor cells, the pharmaceutical composition provided by the invention has the advantages of reducing the dosage, shortening the treatment period and reducing the occurrence of toxic and side reactions.

The invention discloses a recombinant human chorionic gonadotrophin-Fc fusion protein (HCG-Fc for short) and a preparation method thereof. The HCG-Fc protein is a dimerized fusion protein, and the amino acid sequence of the fusion protein sequentially comprises an HCG beta subunit, an HCG alpha subunit, a flexible peptide joint and a human IgG Fc mutant from an N end to a C end. Compared with the existing chorionic gonadotrophin, the fusion protein has longer in-vivo half life, higher bioavailability and lower side effect. The invention also relates to an application of a recombinant HCG-Fc fusion protein composition in preparation of medicaments for treating and / or preventing infertility.